NEW YORK (GenomeWeb News) – The Oxford Biomedical Research Centre will install several 454 GS FLX sequencing instruments and will use NimbleGen arrays to conduct genome-wide studies focused on finding links between human diseases and genetic mutations, 454 and NimbleGen parent company Roche said Thursday.
OxBRC is a partnership between Oxford Radcliffe Hospitals NHS Trust and the University of Oxford.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.